William R. Gwin III, MD

home / authors / william-r-gwin-iii-md

Articles

Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast Cancer

Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast Cancer

William R. Gwin III, MD
June 16th 2020

William R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.

Read More

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

William R. Gwin III, MD
June 5th 2020

William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.

Read More

Dr. Gwin on the Safety of α-TEA Plus Trastuzumab in Recurrent HER2+ Breast Cancer

Dr. Gwin on the Safety of α-TEA Plus Trastuzumab in Recurrent HER2+ Breast Cancer

William R. Gwin III, MD
June 3rd 2020

William R. Gwin III, MD, discusses the safety profile of alpha-tocopheryloxyacetic acid in combination with trastuzumab in recurrent HER2-positive metastatic breast cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data